Lu Yong-ning, Chen Bin
Department of Urology, Shanghai Institute of Andrology, Renji Hospital Affiliated to Shanghai Second Medical University, Shanghai 200001, China.
Zhonghua Nan Ke Xue. 2005 Jul;11(7):552-5.
Erectile dysfunction is a common ailment in middle-aged and old men. The management of ED has entered a new stage since sildenafil was used to treat ED in 1998. Sildenafil became the first-line treatment for its efficacy and safety. In recent years, new PDE5 inhibitors--vardenafil and tadalafil came into market in succession, providing more options available for oral therapy. This review is about the development of preclinical and clinical medicine research on the three PDE5 inhibitors, and provide information for clinical choices.
勃起功能障碍是中老年男性的常见疾病。自1998年西地那非用于治疗勃起功能障碍以来，勃起功能障碍的治疗进入了一个新阶段。西地那非因其有效性和安全性成为一线治疗药物。近年来，新型磷酸二酯酶5（PDE5）抑制剂伐地那非和他达拉非相继上市，为口服治疗提供了更多选择。本文综述了这三种PDE5抑制剂的临床前和临床医学研究进展，为临床选择提供参考。
